Annual D&A
$5.39 B
+$133.00 M+2.53%
31 December 2023
Summary:
AstraZeneca annual depreciation & amortization is currently $5.39 billion, with the most recent change of +$133.00 million (+2.53%) on 31 December 2023. During the last 3 years, it has risen by +$2.49 billion (+86.02%). AZN annual D&A is now at all-time high.AZN Depreciation And Amortization Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Quarterly D&A
$1.82 B
+$538.00 M+42.06%
30 September 2024
Summary:
AstraZeneca quarterly depreciation & amortization is currently $1.82 billion, with the most recent change of +$538.00 million (+42.06%) on 30 September 2024. Over the past year, it has increased by +$535.00 million (+41.73%). AZN quarterly D&A is now -34.83% below its all-time high of $2.79 billion, reached on 30 September 2021.AZN Quarterly D&A Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
TTM D&A
$5.22 B
+$535.00 M+11.41%
30 September 2024
Summary:
AstraZeneca TTM depreciation & amortization is currently $5.22 billion, with the most recent change of +$535.00 million (+11.41%) on 30 September 2024. Over the past year, it has dropped by -$89.00 million (-1.67%). AZN TTM D&A is now -4.08% below its all-time high of $5.45 billion, reached on 31 March 2023.AZN TTM D&A Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
AZN Depreciation And Amortization Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | +2.5% | +41.7% | -1.7% |
| 3 y3 years | +86.0% | -34.8% | +7.0% |
| 5 y5 years | +43.5% | +153.8% | +38.2% |
AZN Depreciation And Amortization High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3 years | at high | +86.0% | -34.8% | +869.9% | -4.1% | +38.8% |
| 5 y | 5 years | at high | +86.0% | -34.8% | +869.9% | -4.1% | +83.2% |
| alltime | all time | at high | +2119.9% | -34.8% | +869.9% | -4.1% | +1904.5% |
AstraZeneca Depreciation And Amortization History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sept 2024 | - | $1.82 B(+42.1%) | $5.22 B(+11.4%) |
| June 2024 | - | $1.28 B(+1.9%) | $4.69 B(+0.1%) |
| Mar 2024 | - | $1.25 B(+43.6%) | $4.69 B(-5.0%) |
| Dec 2023 | $5.39 B(+2.5%) | $874.00 M(-31.8%) | $4.93 B(-7.2%) |
| Sept 2023 | - | $1.28 B(+0.5%) | $5.31 B(-1.0%) |
| June 2023 | - | $1.28 B(-15.0%) | $5.37 B(-1.5%) |
| Mar 2023 | - | $1.50 B(+19.8%) | $5.45 B(+3.7%) |
| Dec 2022 | $5.25 B(+28.1%) | $1.25 B(-6.0%) | $5.25 B(+39.6%) |
| Sept 2022 | - | $1.33 B(-1.7%) | $3.76 B(-27.9%) |
| June 2022 | - | $1.36 B(+3.7%) | $5.22 B(+13.1%) |
| Mar 2022 | - | $1.31 B(-654.7%) | $4.61 B(+12.5%) |
| Dec 2021 | $4.10 B(+41.6%) | -$236.00 M(-108.5%) | $4.10 B(-16.0%) |
| Sept 2021 | - | $2.79 B(+270.3%) | $4.88 B(+68.6%) |
| June 2021 | - | $753.00 M(-5.5%) | $2.90 B(+1.5%) |
| Mar 2021 | - | $797.00 M(+46.5%) | $2.85 B(-1.5%) |
| Dec 2020 | $2.90 B(-23.0%) | $544.00 M(-32.1%) | $2.90 B(-27.5%) |
| Sept 2020 | - | $801.00 M(+12.8%) | $4.00 B(+2.2%) |
| June 2020 | - | $710.00 M(-15.6%) | $3.91 B(-0.4%) |
| Mar 2020 | - | $841.00 M(-48.8%) | $3.93 B(+4.4%) |
| Dec 2019 | $3.76 B(+0.2%) | $1.64 B(+129.5%) | $3.76 B(-0.5%) |
| Sept 2019 | - | $716.00 M(-1.5%) | $3.78 B(+0.5%) |
| June 2019 | - | $727.00 M(+7.5%) | $3.76 B(+1.2%) |
| Mar 2019 | - | $676.00 M(-59.3%) | $3.72 B(-0.9%) |
| Dec 2018 | $3.75 B(+23.6%) | $1.66 B(+138.1%) | $3.75 B(+17.4%) |
| Sept 2018 | - | $698.00 M(+2.0%) | $3.20 B(+1.4%) |
| June 2018 | - | $684.00 M(-3.5%) | $3.15 B(+2.2%) |
| Mar 2018 | - | $709.00 M(-36.0%) | $3.09 B(+1.7%) |
| Dec 2017 | $3.04 B(+28.8%) | $1.11 B(+69.0%) | $3.04 B(+20.5%) |
| Sept 2017 | - | $655.00 M(+6.3%) | $2.52 B(+1.8%) |
| June 2017 | - | $616.00 M(-6.4%) | $2.48 B(+1.2%) |
| Mar 2017 | - | $658.00 M(+11.5%) | $2.45 B(+3.8%) |
| Dec 2016 | $2.36 B(-17.4%) | $590.00 M(-3.4%) | $2.36 B(-5.1%) |
| Sept 2016 | - | $611.00 M(+4.1%) | $2.48 B(+1.6%) |
| June 2016 | - | $587.00 M(+3.2%) | $2.44 B(-5.0%) |
| Mar 2016 | - | $569.00 M(-20.5%) | $2.57 B(-9.8%) |
| Dec 2015 | $2.85 B(-13.1%) | $716.00 M(+25.4%) | $2.85 B(-9.7%) |
| Sept 2015 | - | $571.00 M(-20.3%) | $3.16 B(-8.1%) |
| June 2015 | - | $716.00 M(-15.7%) | $3.44 B(+0.5%) |
| Mar 2015 | - | $849.00 M(-16.8%) | $3.42 B(+4.2%) |
| Dec 2014 | $3.28 B(-28.4%) | $1.02 B(+20.0%) | $3.28 B(-32.6%) |
| Sept 2014 | - | $851.00 M(+21.9%) | $4.87 B(+10.5%) |
| June 2014 | - | $698.00 M(-2.0%) | $4.40 B(-5.2%) |
| Mar 2014 | - | $712.00 M(-72.7%) | $4.64 B(+1.3%) |
| Dec 2013 | $4.58 B(+82.0%) | $2.60 B(+571.4%) | $4.58 B(+67.1%) |
| Sept 2013 | - | $388.00 M(-58.7%) | $2.74 B(-11.5%) |
| June 2013 | - | $939.00 M(+44.2%) | $3.10 B(+16.1%) |
| Mar 2013 | - | $651.00 M(-14.8%) | $2.67 B(+6.0%) |
| Dec 2012 | $2.52 B(-1.3%) | $764.00 M(+2.6%) | $2.52 B(-7.6%) |
| Sept 2012 | - | $745.00 M(+46.1%) | $2.72 B(+8.0%) |
| June 2012 | - | $510.00 M(+2.2%) | $2.52 B(-0.0%) |
| Mar 2012 | - | $499.00 M(-48.6%) | $2.52 B(-1.1%) |
| Dec 2011 | $2.55 B | $970.00 M(+78.6%) | $2.55 B(-11.7%) |
| Sept 2011 | - | $543.00 M(+6.3%) | $2.89 B(-2.0%) |
| June 2011 | - | $511.00 M(-2.9%) | $2.95 B(+2.8%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Mar 2011 | - | $526.00 M(-59.8%) | $2.87 B(+4.6%) |
| Dec 2010 | $2.74 B(+31.3%) | $1.31 B(+117.1%) | $2.74 B(+24.1%) |
| Sept 2010 | - | $602.00 M(+39.7%) | $2.21 B(+6.7%) |
| June 2010 | - | $431.00 M(+7.5%) | $2.07 B(-1.6%) |
| Mar 2010 | - | $401.00 M(-48.3%) | $2.10 B(+0.8%) |
| Dec 2009 | $2.09 B(-20.3%) | $775.00 M(+67.4%) | $2.09 B(-6.8%) |
| Sept 2009 | - | $463.00 M(-0.2%) | $2.24 B(-2.9%) |
| June 2009 | - | $464.00 M(+20.5%) | $2.31 B(+0.1%) |
| Mar 2009 | - | $385.00 M(-58.5%) | $2.30 B(-12.1%) |
| Dec 2008 | $2.62 B(+41.2%) | $927.00 M(+74.9%) | $2.62 B(+16.7%) |
| Sept 2008 | - | $530.00 M(+15.0%) | $2.25 B(-1.5%) |
| June 2008 | - | $461.00 M(-34.3%) | $2.28 B(+4.2%) |
| Mar 2008 | - | $702.00 M(+27.2%) | $2.19 B(+17.9%) |
| Dec 2007 | $1.86 B(+38.0%) | $552.00 M(-2.3%) | $1.86 B(+7.2%) |
| Sept 2007 | - | $565.00 M(+53.1%) | $1.73 B(+15.8%) |
| June 2007 | - | $369.00 M(-0.3%) | $1.50 B(+4.4%) |
| Mar 2007 | - | $370.00 M(-13.6%) | $1.43 B(+6.5%) |
| Dec 2006 | $1.34 B(+1.4%) | $428.00 M(+30.1%) | $1.34 B(+2.6%) |
| Sept 2006 | - | $329.00 M(+7.5%) | $1.31 B(+2.0%) |
| June 2006 | - | $306.00 M(+8.5%) | $1.28 B(-1.2%) |
| Mar 2006 | - | $282.00 M(-28.4%) | $1.30 B(-2.0%) |
| Dec 2005 | $1.33 B(+4.7%) | $394.00 M(+30.0%) | $1.33 B(+1.7%) |
| Sept 2005 | - | $303.00 M(-5.6%) | $1.30 B(+0.9%) |
| June 2005 | - | $321.00 M(+3.9%) | $1.29 B(+1.4%) |
| Mar 2005 | - | $309.00 M(-16.9%) | $1.27 B(+0.6%) |
| Dec 2004 | $1.27 B(-1.9%) | $372.00 M(+27.8%) | $1.27 B(-1.6%) |
| Sept 2004 | - | $291.00 M(-4.0%) | $1.29 B(-12.9%) |
| June 2004 | - | $303.00 M(+0.3%) | $1.48 B(+11.9%) |
| Mar 2004 | - | $302.00 M(-23.2%) | $1.32 B(+2.3%) |
| Dec 2003 | $1.29 B(+34.7%) | $393.00 M(-18.4%) | $1.29 B(+11.3%) |
| Sept 2003 | - | $481.84 M(+230.7%) | $1.16 B(+26.4%) |
| June 2003 | - | $145.71 M(-46.5%) | $919.16 M(-8.6%) |
| Mar 2003 | - | $272.45 M(+4.2%) | $1.01 B(+4.7%) |
| Dec 2002 | $960.00 M(+11.6%) | $261.54 M(+9.2%) | $960.00 M(+3.7%) |
| Sept 2002 | - | $239.46 M(+3.2%) | $925.46 M(+3.4%) |
| June 2002 | - | $232.00 M(+2.2%) | $895.00 M(+2.2%) |
| Mar 2002 | - | $227.00 M(0.0%) | $875.69 M(+1.8%) |
| Dec 2001 | $860.00 M(-7.4%) | $227.00 M(+8.6%) | $860.00 M(+8.8%) |
| Sept 2001 | - | $209.00 M(-1.7%) | $790.44 M(-5.9%) |
| June 2001 | - | $212.69 M(+0.7%) | $839.96 M(-4.5%) |
| Mar 2001 | - | $211.31 M(+34.2%) | $879.67 M(-5.3%) |
| Dec 2000 | $929.02 M(-13.1%) | $157.44 M(-39.1%) | $929.02 M(+20.4%) |
| Sept 2000 | - | $258.52 M(+2.4%) | $771.59 M(+50.4%) |
| June 2000 | - | $252.40 M(-3.2%) | $513.07 M(+96.8%) |
| Mar 2000 | - | $260.66 M | $260.66 M |
| Dec 1999 | $1.07 B(+30.2%) | - | - |
| Dec 1998 | $821.00 M(+129.9%) | - | - |
| Dec 1997 | $357.07 M(-3.9%) | - | - |
| Dec 1996 | $371.61 M(+24.0%) | - | - |
| Dec 1995 | $299.77 M(+8.3%) | - | - |
| Dec 1994 | $276.72 M(+8.8%) | - | - |
| Dec 1993 | $254.42 M(+4.8%) | - | - |
| Dec 1992 | $242.67 M(-16.9%) | - | - |
| Dec 1991 | $291.91 M(-3.0%) | - | - |
| Dec 1990 | $300.91 M | - | - |
FAQ
- What is AstraZeneca annual depreciation & amortization?
- What is the all time high annual D&A for AstraZeneca?
- What is AstraZeneca annual D&A year-on-year change?
- What is AstraZeneca quarterly depreciation & amortization?
- What is the all time high quarterly D&A for AstraZeneca?
- What is AstraZeneca quarterly D&A year-on-year change?
- What is AstraZeneca TTM depreciation & amortization?
- What is the all time high TTM D&A for AstraZeneca?
- What is AstraZeneca TTM D&A year-on-year change?
What is AstraZeneca annual depreciation & amortization?
The current annual D&A of AZN is $5.39 B
What is the all time high annual D&A for AstraZeneca?
AstraZeneca all-time high annual depreciation & amortization is $5.39 B
What is AstraZeneca annual D&A year-on-year change?
Over the past year, AZN annual depreciation & amortization has changed by +$133.00 M (+2.53%)
What is AstraZeneca quarterly depreciation & amortization?
The current quarterly D&A of AZN is $1.82 B
What is the all time high quarterly D&A for AstraZeneca?
AstraZeneca all-time high quarterly depreciation & amortization is $2.79 B
What is AstraZeneca quarterly D&A year-on-year change?
Over the past year, AZN quarterly depreciation & amortization has changed by +$535.00 M (+41.73%)
What is AstraZeneca TTM depreciation & amortization?
The current TTM D&A of AZN is $5.22 B
What is the all time high TTM D&A for AstraZeneca?
AstraZeneca all-time high TTM depreciation & amortization is $5.45 B
What is AstraZeneca TTM D&A year-on-year change?
Over the past year, AZN TTM depreciation & amortization has changed by -$89.00 M (-1.67%)